Abstracts tagged "drug survival"

Abstract Number: 934 • 2019 ACR/ARP Annual Meeting
Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis
Benoit Flachaire¹, Jean-Guillaume Letarouilly ², Céline Labadie ³, Nicolas Cohen ⁴, Vincent Pradel ⁵, Jérémie Sellam ⁶, Pascal Richette ⁷, Philippe Dieudé ⁸, Pascal Claudepierre ⁹, Bruno Fautrel ¹⁰, Eric Houvenagel ¹¹, Chi Duc Nguyen ¹², Marie-Hélène Guyot ¹³, Nicolas Segaud ¹⁴, Frédéric Maury ¹⁵, Laurent Marguerie ¹⁶, Xavier Deprez ¹⁷, Jean-Hugues Salmon ¹⁸, Guy Baudens ¹⁹, Elisabeth Gervais ²⁰, Corinne Miceli-Richard ²¹, Isabelle Chary-Valckenaere ²², Pierre Lafforgue ²³, Damien Loeuille ²⁴, Christophe Richez ²⁵, René-Marc Flipo ²⁶ and Thao Pham ²³, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ²University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴APHM -Assistance publique des hôpitaux de Marseille, Marseille, France, ⁵APHM -Assistance publique des hôpitaux de Marseille, Marseille, Finland, ⁶Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁸Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁹Rheumatology, CHU Henri Mondor Créteil, Paris, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ¹¹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹²Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹³Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹⁴Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹⁵Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁶Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁷Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁸Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁹Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ²⁰CHU de Poitiers, Rheumatology, Poitiers, France, ²¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²²Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²³Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²⁴Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²⁵Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²⁶University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Secukinumab (SEC) is an interleukin-17 inhibitor used to treat patients with axial spondylarthritis (axSpA) and psoriatic arthritis (PsA). Drug survival is often used as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].